Literature DB >> 20428656

Seroprevalence of hepatitis B and hepatitis C markers among children and adolescents in the south Brazilian region: metropolitan area of Florianópolis, Santa Catarina.

Andréia Royer Voigt1, Miguel Strazer Neto, Celso Spada, Arício Treitinger.   

Abstract

Hepatitis B and C are important causes of morbidity and mortality worldwide. In Brazil, according to the Ministry of Health, about 15% of population is infected by hepatitis B virus (HBV) and less than 1% by hepatitis C virus (HCV). Nevertheless, the age-specific prevalence of HBV and HCV markers remains unknown. This study aimed to determine the seroprevalence of HBV and HCV markers of infection and immunity in children and adolescents between 10 to 16 years old who live in the metropolitan area of Florianópolis, state of Santa Catarina, South of Brazil. Three hundred and eighty four individuals were enrolled in this study. Serological markers for HBV and HCV (HBsAg, total anti-HBc, anti-HBc IgM, anti-HBs and anti-HCV) were determined through Microparticle Enzyme Immunosorbant Assay (MEIA) - AxSYM System - by using commercial diagnostic kits (Abbott Laboratories, Abbott Park, Illinois, USA). All 384 adolescents (100%) were negative for HBsAg and anti-HBc IgM. Only two (0.52%) were positive for total anti-HBc. Among the studied individuals, 226 (58.85%) presented titers of anti-HBs > 10.0mIU/mL, 121 (31.51%) presented anti HBs < 10.0mIU/mL, and 37 (9.64%) did not present titers of anti-HBs. Regarding to anti-HCV, all 384 adolescents (100%) presented negative results for this marker. In conclusion, this study showed a low prevalence of HBV and HCV infections. In addition, it was verified a great number of children and adolescents (89.84%) who were positive for the immunity marker anti-HBs, implying that the National Immunization Program Protocol for hepatitis B has been effective in the studied region.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428656

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  7 in total

1.  The seroprevalence of both hepatitis B and hepatitis C at the first-step health organizations and the difference between the urban and rural areas.

Authors:  Fatma Kalem; Şerife Yüksekkaya; Metin Başaranoğlu
Journal:  Wien Klin Wochenschr       Date:  2015-04-14       Impact factor: 1.704

2.  Hepatitis B: Epidemiology and prevention in developing countries.

Authors:  Elisabetta Franco; Barbara Bagnato; Maria Giulia Marino; Cristina Meleleo; Laura Serino; Laura Zaratti
Journal:  World J Hepatol       Date:  2012-03-27

Review 3.  HIV/HBV coinfection in children and antiviral therapy.

Authors:  Sara A Healy; Sonia Gupta; Ann J Melvin
Journal:  Expert Rev Anti Infect Ther       Date:  2013-03       Impact factor: 5.091

4.  Immunogenicity of Recombinant Hepatitis B Vaccine Among Routinely Vaccinated Healthy and Chronically Ill Children in Assiut, Upper Egypt.

Authors:  Osama M El-Asheer; Manal M Darwish; Madleen A Abdou; Khaled Saad
Journal:  Gastroenterology Res       Date:  2015-07-22

Review 5.  Hepatitis C worldwide and in Brazil: silent epidemic--data on disease including incidence, transmission, prevention, and treatment.

Authors:  Iara Fabricia Kretzer; Andrea do Livramento; Joel da Cunha; Sabrina Gonçalves; Iraci Tosin; Celso Spada; Aricio Treitinger
Journal:  ScientificWorldJournal       Date:  2014-06-10

6.  Low prevalence of hepatitis B and C virus markers among children and adolescents.

Authors:  Livia Melo Villar; Luciane Almeida Amado; Adilson José de Almeida; Vanessa Salete de Paula; Lia Laura Lewis-Ximenez; Elisabeth Lampe
Journal:  Biomed Res Int       Date:  2014-07-01       Impact factor: 3.411

7.  Vaccination coverage and immunity against hepatitis B among HIV-infected patients in South Brazil.

Authors:  Saulo Martins; Andréa do Livramento; Michelle Andrigueti; Iara Fabricia Kretzer; Marcos José Machado; Celso Spada; Arício Treitinger
Journal:  Braz J Infect Dis       Date:  2015-01-24       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.